MedTrace Logo

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

NCT02925793 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 327

Last updated 2022-11-22

Study results available
· View outcomes & findings →

Summary

The purpose of this randomized, double blind, placebo controlled, parallel group study is to compare the safety and efficacy of topically applied DS107 cream (1% and 5%) versus vehicle cream, in the treatment of adult patients with mild to moderate Atopic Dermatitis (AD).

Conditions

Interventions

DRUG

DS107

OTHER

Vehicle cream

Sponsors & Collaborators

  • DS Biopharma

    lead INDUSTRY

Principal Investigators

  • Markus Weissbach, MD, Ph.D · DS Biopharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • United States
  • Canada
  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02925793 on ClinicalTrials.gov